3288 results for «2026年4月7日至2026年4月16日002309主力资金流向情况»
3288 results
Complex valve-in-valve leaflet modification - LIVE Case
17 Nov 2025 – From PCR London Valves 2025
Watch this LIVE case followed by a recorded case, regarding a 79-year-old male with permanent AF and a history of surgical aortic valve replacement in 2010 (Magna Ease 25) who presented with symptomatic bioprosthetic valve stenosis, normal LV function, and no CAD. A Sapien 3 Ultra...
Tricuspid interventions: knowns and unknowns
17 Nov 2025 – From PCR London Valves 2025
Explore the evolving landscape of transcatheter tricuspid valve interventions in this session, which presents the latest evidence from registries and randomized trials. Discussions include the new Euro tricuspid regurgitation risk score, clinical controversies, real-world patient scenarios, and insights into optimal medical therapy and device selection to...
Featured research - TAVI - Part 14
18 Nov 2025 – From PCR London Valves 2025
This featured research session presents pivotal findings on transcatheter aortic valve implantation (TAVI), including 30-day and one-year outcomes from the VANTAGE trial, novel concepts for assessing aortic stenosis severity, and the influence of mitral annular calcification on conduction disturbances. Additional topics cover the role of clinical...
TAVI complications - Part 3
18 Nov 2025 – From PCR London Valves 2025
This session provides a detailed examination of TAVI-related complications and their management. Key topics include the STJ-sling technique, valve frame underexpansion diagnosis, real-time intracardiac echocardiography utility, recurrent cardiac arrest scenarios during TAVI, and management strategies for valve in-folding in self-expanding transcatheter valves.
Mastering mitral TEER: guidelines, complex cases, and Asia Pacific insights
14 Feb 2026 – From PCR Tokyo Valves 2026
Focused on mastering mitral transcatheter edge-to-edge repair (TEER), this session analyzed the 2025 ESC VHD guidelines and their clinical implications. It addressed optimal timing and treatment strategies for severe heart failure beyond the COAPT trial and explored technical solutions for complex anatomies, including customization approaches for...
Mastering techniques from basic to complex - TAVI basics
13 Feb 2026 – From PCR Tokyo Valves 2026
This session offers a comprehensive overview of Transcatheter Aortic Valve Implantation (TAVI) fundamentals, focusing on CT scan analysis for optimal patient and valve selection, strategies to avoid procedural complications, and approaches to streamline TAVI procedures for improved outcomes.
Mastering techniques from basic to complex - Avoidance and management of TAVI complications
13 Feb 2026 – From PCR Tokyo Valves 2026
Address the challenges posed by complex TAVI complications through expert discussion on prevention, management, and bailout techniques. This session covers critical complications such as annulus rupture, stroke, conduction disturbances, and vascular events.
Mastering techniques from basic to complex - Advanced TAVI
13 Feb 2026 – From PCR Tokyo Valves 2026
Explore advanced TAVI topics including valve selection for small annuli, optimization strategies for bicuspid aortic valve interventions, and techniques ensuring safety and efficacy in valve-in-valve procedures.
Mastering LAA closure: a step-by-step case experience
14 Feb 2026 – From PCR Tokyo Valves 2026
Master the step-by-step approach to Left Atrial Appendage (LAA) closure, covering procedural planning, device-specific strategies, complication prevention, and advanced bailout techniques such as leak closure with coiling or dual-device implantation.
Patient-tailored treatment for bicuspid valve
14 Feb 2026 – From PCR Tokyo Valves 2026
Delve into patient-tailored treatment strategies for bicuspid aortic valve stenosis, focusing on evidence-based valve selection and sizing for TAVI candidates. This session reviews current device options, procedural planning considerations, and case studies illustrating the use of balloon-expanding and self-expanding valves, emphasizing challenges posed by unfavourable bicuspid...
Mitral TEER masterclass
14 Feb 2026 – From PCR Tokyo Valves 2026
Delve into the mitral TEER masterclass focusing on unique anatomical challenges encountered in Asian populations. This session presents complex case studies illustrating device strategies and practical techniques aimed at minimizing complications and optimizing procedural outcomes in anatomically challenging scenarios.
All you need to know about redo TAVI
15 Feb 2026 – From PCR Tokyo Valves 2026
This comprehensive session on redo Transcatheter Aortic Valve Implantation (TAVI) covers critical aspects beyond coronary obstruction risk, including detailed pre-procedural analysis, valve sizing, and innovative procedural techniques such as leaflet modification and optimal angle placement. Post-procedural considerations like antithrombotic therapy and patient-prosthesis mismatch are also thoroughly...
Miscellaneous complications: my worst nightmare
15 Feb 2026 – From PCR Tokyo Valves 2026
Explore the prevention and management of complications arising from transcatheter interventions in structural heart disease through challenging case analyses. This session presents real-world scenarios addressing complications encountered during TAVI, mitral, and tricuspid procedures, highlighting strategies to anticipate and manage these critical events effectively.
Procedural imaging for tricuspid valve interventions
15 Feb 2026 – From PCR Tokyo Valves 2026
Dedicated to procedural imaging for tricuspid valve interventions, this session elucidates anatomical and pathophysiological features critical for successful transcatheter procedures. It emphasizes technical aspects of TEE and ICE imaging, including 3D multiplanar reconstruction, and offers case-based learning to refine imaging skills and optimize procedural outcomes.
Mitral and aortic transcatheter valve-in-valve intervention - LIVE case
14 Feb 2026 – From PCR Tokyo Valves 2026
Live case
An 83-year-old male with AF, CKD (stage 3A), preserved LV function, and a history of AVR (27 mm Magna Ease) and MVR (33 mm Magna) in 2014 presented with symptomatic stenosis of the mitral bioprosthesis. A Sapien 3 valve was implanted in the Magna mitral...
TEER in complex tricuspid regurgitation - LIVE case
14 Feb 2026 – From PCR Tokyo Valves 2026
A 79-year-old male with permanent AF, prior colorectal and prostate cancer, and a Mosaic bioprosthetic mitral valve implanted in 2016, presented with torrential tricuspid regurgitation and preserved LV function.
Three G5 clips were implanted: two anteroseptal (1 XTW and 1 XT) and one posteroseptal XTW.
LIVE Educational Case...
Introducing the next era of coronary intravascular lithotripsy: an aero-volution in calcium modification
27 Feb 2026 – From Euro4C Annual Meeting
Explore the next era of coronary intravascular lithotripsy featuring innovative technology for calcium modification. This session covers the unique mechanism of action, practical application in complex cases, and recent clinical evidence supporting its safety and efficacy.
Prevention and management of TAVI complications
14 Feb 2026 – From PCR Tokyo Valves 2026
This session addresses the prevention and management of major complications associated with transcatheter aortic valve implantation (TAVI). Attendees will gain a detailed understanding of mechanisms behind cerebral infarction, haemolysis, valve infolding, pacemaker implantation, and valve migration, along with expert strategies for recognition, decision-making, and bailout techniques...
Novel Hertz Contact intravascular lithotripsy: calcium fragmentation with zero trade-offs
27 Feb 2026 – From Euro4C Annual Meeting
This session introduces the novel Hertz Contact intravascular lithotripsy system, designed for effective calcium fragmentation without trade-offs. It covers lesion types amenable to treatment, system mechanism, optimization tips, and discusses real-world cases along with supporting clinical trial evidence.
Primary mitral TEER in small anatomy - LIVE case
15 Feb 2026 – From PCR Tokyo Valves 2026
An 89-year-old male with diabetes mellitus, hypertension, chronic kidney disease (eGFR: 46), and CAD with a history of NSTEMI and CTO of the RCA, presented with symptomatic primary mitral regurgitation (P1–P2 prolapse) and preserved LV function (56%).
One Pascal ACE device was implanted.
LIVE Educational Case from Nagoya...
